Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamapimod/pioglitazone - Curatis

Next Previous
Drug Profile

Pamapimod/pioglitazone - Curatis

Alternative Names: KIN-001; KIN001-AMD; KIN001-IPF; KINFAST; Pioglitazone/pamapimod - Curatis

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kinarus AG
  • Developer Curatis
  • Class Alcohols; Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antirheumatics; Antivirals; Eye disorder therapies; Pyridines; Pyridones; Pyrimidines; Small molecules; Thiazolidinediones
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; PPAR gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections; Wet age-related macular degeneration
  • Preclinical Rheumatoid arthritis
  • No development reported Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in Switzerland (PO, Liquid)
  • 03 Oct 2023 Kinarus AG suspends a phase II KIN-FAST trial in COVID-2019 infections in Germany and Switzerland (PO), due to financial issues (NCT05659459)
  • 03 Jan 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top